Lifeboat Foundation

Article at gnews reports on announcement by Dr. Ozaki, chairman of the Tokyo Metropolitan Medical Association Greenlight for Ivermectin in Japan. Excerpts in italics with my bolds.

Since Tokyo summer Olympic Game ended on August 8 2021, the urgent status of the pandemic as Japan is now in its worst surge of the COVID-19 pandemic since the onset of the crisis in such a megacity of 14 million. Most recently, a record number of new cases were reported at 20,140 on August 14. Deaths aren’t as high as successive waves of the pandemic from February2021to the end of May, but nerves are frayed with record numbers of infections. Dr. Ozaki, The chairman of the Tokyo Metropolitan Medical Association, recently led an emergency press conference on August 13 Dr. Haruo Ozaki shared those 18,000 new infections are reported daily. However, the death count has eased as compared to previous surges.

How to deal with the current dilemma is a huge challenge to Japanese government and medical agencies? Fortunately, India has an excellent testimonial. Since April 28 India medical officials started providing Hydroxychloroquine and ivermectin to its massive population. As India is the major pharmaceutical manufacture in the world, they were ready for this massive drug distribution. Miraculously, COVID cases have plummeted quickly since then thanks to the new rules.

After successful completion of its final tests, NASA

Established in 1,958 the National Aeronautics and Space Administration (NASA) is an independent agency of the United States Federal Government that succeeded the National Advisory Committee for Aeronautics (NACA). It is responsible for the civilian space program, as well as aeronautics and aerospace research. It’s vision is “To discover and expand knowledge for the benefit of humanity.”

Can this be true?

Elon Musk has criticized fellow centibillionaire and space cowboy Jeff Bezos for filing lawsuits against the former’s aerospace company SpaceX.

Earlier this month, Bezos’ space firm Blue Origin sued NASA after it lost a critical government contract to put astronauts on the Moon to SpaceX. This has had the effect of delaying SpaceX’s own work on the project. And now, this week, Amazon has urged the Federal Communications Commission (FCC) to dismiss newly-submitted plans by SpaceX to launch another cluster of satellites to power its satellite internet service Starlink.

Continue reading “Elon Musk: ‘Bezos retired in order to pursue a full-time job filing lawsuits against SpaceX’” »

The mRNA vaccine success story is one of the few positives to emerge from COVID-19. But these vaccines from Moderna and Pfizer/BioNTech are only the tip of the iceberg in the coming RNA medical technology revolution.

Australia, including our newly established UNSW RNA Institute, is well-placed to take a leading role in this revolution. With its eyes firmly set on making NSW a global force in the RNA industry, the NSW Government is backing a new RNA Bioscience Alliance between all the NSW Universities as well as funding a $15 million RNA production network between some of the state’s leading research organizations to bootstrap pre-clinical RNA research. UNSW’s RNA Institute is a key part of this drive, and with a $25 million investment brings together world-leading expertise to support the state and national agenda.

So beyond mRNA vaccines, what are these RNA therapeutics on the horizon? And what is the secret sauce that finally got mRNA vaccines to work after many years of trying? To understand this, let’s first tackle what RNA is and how it is used in medicine.

El Salvador began installing Bitcoin ATMs, allowing its citizens to convert the cryptocurrency into U.S. dollars and withdraw it in cash, as part of the government’s plan to make the token legal tender.

The government will install 200 of the teller machines to initially accompany its digital wallet called Chivo, a local slang term for ‘cool,’ President Nayib Bukele said on Twitter. Transactions will be commission free, he said, adding that there will also be 50 financial branches across the country for withdrawing or depositing money.

Jackson continues by saying that blue hydrogen is “at best an expensive distraction, and at worst a lock-in for continued fossil fuel use” which would derail goals that the country and the world have set for decarbonizing the economy. He takes particular issue with the fact that oil and gas companies have asked the UK government for decades of subsidies while also claiming that blue hydrogen will be inexpensive to produce. “If the false claims made by oil companies about the cost of blue hydrogen were true, their projects would make a profit by 2030,” he told The Guardian.

Recent studies have questioned blue hydrogen’s low-carbon bona fides.

Economists have learned that new technological breakthroughs usually don’t cause a jump in productivity right away. The technology needs time to marinate so companies can test how best to deploy it in their industry. Brynjolfsson argues artificial intelligence and machine learning have now simmered long enough to make a dramatic difference. Others are not as convinced.

Rapid adoption of robots and artificial intelligence during the pandemic combined with a rebound in government investment is making some economists optimistic about a return of a 1990s economy with widespread benefits.

Battery-and carmakers are already spending billions of dollars on reducing the costs of manufacturing and recycling electric-vehicle (EV) batteries — spurred in part by government incentives and the expectation of forthcoming regulations. National research funders have also founded centres to study better ways to make and recycle batteries. Because it is still less expensive, in most instances, to mine metals than to recycle them, a key goal is to develop processes to recover valuable metals cheaply enough to compete with freshly mined ones. “The biggest talker is money,” says Jeffrey Spangenberger, a chemical engineer at Argonne National Laboratory in Lemont, Illinois, who manages a US federally funded lithium-ion battery-recycling initiative, called ReCell.

Reducing the use of scarce metals — and recycling them — will be key to the world’s transition to electric vehicles.

Jeff Bezos’s Blue Origin is challenging a U.S. government contract with Elon Musk’s SpaceX to develop technology to land people on the moon again.

In a complaint filed Friday in the Court of Federal Claims in Washington, Blue Origin said the National Aeronautics and Space Administration’s evaluation process was “unlawful and improper.” The complaint was filed under seal but tandem documents seeking a protective order gave an indication of its contents.

NASA selected SpaceX’s human lander bid on April 16 leading Blue Origin and a bidding partner, Dynetics Inc., to file protests with the Government Accountability Office less than two weeks later alleging that the award process was flawed. The GAO denied that protest on July 30 saying that NASA’s SpaceX selection had been made properly. Blue Origin, which has offered to contribute more than $2 billion of work on the project at no cost to the government, had vowed to continue pursuing the matter.